AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron che...
The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gi...
Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation of small molecule ...
Meiji Seika Pharma Co., Ltd. announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodieste...
As artificial intelligence becomes increasingly embedded in formulation science and early clinical planning, the industry faces a dual challenge: accelerat...
New indications expand treatment options for appropriate children aged 2.5 years and older with Idiopathic Short Stature (ISS), born Small for Ges...
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as mono...
Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutic...
Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), see...
MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health ...
First clinical development program in sporadic ALS patients to show potential to restore STATHMIN-2 expression, a statistically significant effect on a...
Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA) ImmunityBio establi...
Priority Review Granted, Prescription Drug User Fee Act (PDUFA) Target Action Date Set for August 22, 2026 -- -- Company Plans to Submit the MOLBREEV...
-Financing led by Forbion, joined by Sanofi and existing investors Medicxi, Pitango, and Atlantic Partners- -Proceeds to advance vapendavir, a first-in-...
© 2026 Biopharma Boardroom. All Rights Reserved.
